Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan, +15

Nature

MedicineKinase InhibitorsAnti-cancer AgentPharmacologyCancer Growth +4

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, +13

Journal of Clinical Oncology

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, +17

The Lancet Oncology

Lymphoid NeoplasiaBispecific AntibodyMedicineImmunologyImmune Checkpoint Inhibitor +5

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, +20

The Lancet Haematology

Lymphoid NeoplasiaPinatuzumab VedotinMedicinePolatuzumab VedotinMalignant Blood Disorder +7

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang, +16

Cancer Research

Breast OncologyHer2 HomodimersImmunologyPathologyHer2 Gene Amplification +15

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, +12

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMedicinePolatuzumab VedotinImmunology +5

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

Adam R. Johnson, Pawan Bir Kohli, Arna Katewa, +18

ACS Chemical Biology

Thr474 MutationsDrug TargetTyrosine KinaseMolecular BiologyBtk Mutants +16

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha, +25

Clinical Cancer Research

Transformation by v-Src: Ras-MAPK and PI3K-mTOR Mediate Parallel Pathways

Elicia Penuel, Greg S. Martin

Molecular Biology of the Cell

Pi3k-mtor PathwaySignal RecognitionMolecular BiologyCell ProliferationMtor Inhibitor Rapamycin +16

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean, +15

Frontiers in Oncology